Enhabit, Inc. (EHAB) - Stock Analysis

Last updated: Apr 26, 2026

HealthcareClosed

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

An agreed all-cash buyout at $13.80/share by Kinderhook, improving Q4 cash flow, and a recent ~30% deal-driven jump make Enhabit an event-arbitrage opportunity with potential spread compression toward the deal price as litigation and process milestones around the March 4–5 earnings window unfold.

Loading chart data...

Idea window: 2/26/2026 – 3/5/2026Sector: Healthcare

AI Analyst Overview

Last Price
$13.76
Market Cap
$703.58M
1D Return
+0.15%
YTD Return
+49.24%

Loading chart data...

Valuation Metrics

P/E
-151.4
P/B
1.3
P/S
0.7
EV/EBITDA
13.3
Div Yield
—

Fundamental Analysis

5.0

Key Financial Insights: • Cash generation • Thin margins • High leverage EHAB has solid revenue scale, strong cash flow, and decent liquidity, but thin and inconsistent profitability, meaningful leverage, and rich valuation make the stock look stretched versus earnings power.

cashflow
overvalued

Price Behavior

5.0

Key Price Behavior Insights: • Tight Range • Failed Breakout • Firm Support Support Level: $13.60-$13.66 Resistance Level: $13.99-$14.09 EHAB has been range-bound over the last month, holding support near $13.60-$13.66 but losing momentum after a failed breakout to $14.09, so buyers need to reclaim $14.00 to turn the setup more bullish.

neutral
negative

Sentiment & News

6.0

Key News Insights: • Sale vote • Price scrutiny • Hold outlook Enhabit's stock is now primarily driven by the pending Kinderhook sale vote at $13.80/share, but legal challenges and mixed analyst sentiment keep uncertainty elevated.

merger
lawsuit
AI

AI Summary

6.0
Neutral

EHAB should now be viewed primarily as a merger-arbitrage trade with a defined cash exit rather than a standalone turnaround, so the key investment question is whether the Kinderhook deal closes on time and on terms amid shareholder-law noise and residual regulatory/process risk, while the underlying business only needs to stay sufficiently stable to bridge the transaction.

MergerArbitrage
DealRisk
CashFlow
AI summary updated 2 days ago

Description

Enhabit, Inc. is a U.S. provider of home health and hospice care, offering clinical services such as skilled nursing, therapy, disease-specific care and hospice support that address medical, emotional and psychosocial needs. The company operates a network of home health and hospice agencies across multiple states and, as of March 2022, managed 252 home health and 99 hospice agencies in 34 states. Headquartered in Dallas, Texas, Enhabit was incorporated in 2014, changed its name in March 2022, and began operating as a standalone company in July 2022.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Feb 26Mar 5EHABEnhabit, Inc.
An agreed all-cash buyout at $13.80/share by Kinderhook, improving Q4 cash flow, and a recent ~30% deal-driven jump make Enhabit an event-arbitrage opportunity with potential spread compression toward the deal price as litigation and process milestones around the March 4–5 earnings window unfold.
Closed+0.1%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.